| Name | Title | Contact Details |
|---|
Assisted Living Concepts, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Assisted Living Concepts, Inc. is based in Menomonee Falls, WI. You can find more information on Assisted Living Concepts, Inc. at www.alcco.com
Elorac Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Vernon Hills, IL. To find more information about Elorac Inc., please visit www.eloracpharma.com
Family HealthCare Network is a private nonprofit organization that operates 20 sites, 16 of which are federally qualified health centers located throughout Tulare and Kings Counties. Our mission is to provide quality health care to everyone in the communities we serve. With more than 160 medical and dental providers in our network, we provide access to a wide range of coordinated health services. FHCN also offers pharmacy services, free transportation, and extended evening and weekend hours. FHCN is recognized by the National Committee for Quality Assurance (NCQA) as a Level 3 Patient Centered Medical Home and is dually recognized by The Joint Commission with its Gold Seal of Approval® for Patient Quality and Safety and as a Patient Centered Primary Medical Home.
Slimsational Solutions is a Windham, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.